PTC Therapeutics, Inc. (PTC) is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC applies proprietary technologies and our extensive knowledge of post-transcriptional control processes in our drug discovery and development activities. Our preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including genetic disorders, oncology and infectious disease. Our lead product candidate is ataluren for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Ataluren is in late stage clinical development.